From: Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
24 h | 48 h | |||||||
---|---|---|---|---|---|---|---|---|
Ponatinb (nM) | Ponatinb (nM) | |||||||
Cell line | 25 | 50 | 100 | 25 | 50 | 100 | ||
BV-173 | AZD-1775 (nM) | 6.9 | 0.39 | 0.57 | 1.16 | 0.29 | 0.31 | 0.67 |
20.6 | 0.34 | 0.59 | 1.04 | 0.33 | 0.34 | 0.50 | ||
61.7 | 0.33 | 0.55 | 0.99 | 0.16 | 0.17 | 0.56 | ||
185.2 | 0.31 | 0.49 | 0.90 | 0.06 | 0.11 | 0.48 | ||
555.6 | 0.47 | 0.53 | 0.83 | 0.02 | 0.07 | 0.20 | ||
1666.7 | 0.53 | 0.58 | 0.86 | 0.01 | 0.01 | 0.12 | ||
5000.0 | 1.23 | 1.33 | 1.38 | 0.06 | 0.07 | 0.15 | ||
Imatinib (nM) | Imatinib (nM) | |||||||
Cell line | 250 | 500 | 1000 | 250 | 500 | 1000 | ||
BV-173 | AZD-1775 (nM) | 6.9 | 0.39 | 0.41 | 0.62 | 0.41 | 0.03 | 0.02 |
20.6 | 0.58 | 0.43 | 0.69 | 0.43 | 0.04 | 0.03 | ||
61.7 | 0.32 | 0.33 | 0.39 | 0.18 | 0.06 | 0.05 | ||
185.2 | 0.23 | 0.31 | 0.47 | 0.15 | 0.07 | 0.05 | ||
555.6 | 0.50 | 0.44 | 0.48 | 0.11 | 0.08 | 0.07 | ||
1666.7 | 0.57 | 0.50 | 0.53 | 0.07 | 0.20 | 0.17 | ||
5000.0 | 1.05 | 1.18 | 1.21 | 0.61 | 1.19 | 1.56 |